Search hospitals

>

North Carolina

>

Durham

Durham VA Medical Center, Durham, NC

Claim this profile

Durham, North Carolina 27705

Global Leader in Lung Cancer

Global Leader in Post-Traumatic Stress Disorder

Conducts research for Prostate Cancer

Conducts research for Cancer

Conducts research for Non-Small Cell Lung Cancer

335 reported clinical trials

42 medical researchers

Photo of Durham VA Medical Center, Durham, NC in DurhamPhoto of Durham VA Medical Center, Durham, NC in DurhamPhoto of Durham VA Medical Center, Durham, NC in Durham

Summary

Durham VA Medical Center, Durham, NC is a medical facility located in Durham, North Carolina. This center is recognized for care of Lung Cancer, Post-Traumatic Stress Disorder, Prostate Cancer, Cancer, Non-Small Cell Lung Cancer and other specialties. Durham VA Medical Center, Durham, NC is involved with conducting 335 clinical trials across 407 conditions. There are 42 research doctors associated with this hospital, such as Michael J. Kelley, Gerald Grant, MD, Rhonda Bitting, MD, and Daphne R. Friedman.

Area of expertise

1

Lung Cancer

Global Leader

Durham VA Medical Center, Durham, NC has run 43 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage III
Stage II
2

Post-Traumatic Stress Disorder

Global Leader

Durham VA Medical Center, Durham, NC has run 37 trials for Post-Traumatic Stress Disorder.

Top PIs

Clinical Trials running at Durham VA Medical Center, Durham, NC

Lung Cancer

Prostate Cancer

Cancer

Post-Traumatic Stress Disorder

Non-Small Cell Lung Cancer

Lymphoma

Bladder Cancer

Chronic Lymphocytic Leukemia

Pancreatic Cancer

Multiple Myeloma

Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.

Recruiting

2 awards

Phase 3

27 criteria

Image of trial facility.

Chemotherapy + Immunotherapy vs. Immunotherapy

for Advanced Lung Cancer

This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab and chemotherapy may help stabilize lung cancer.

Recruiting

2 awards

Phase 3

Image of trial facility.

Cemiplimab

for Non-Small Cell Lung Cancer

This phase II/III Expanded Lung-MAP treatment trial compares the effect of adding cemiplimab to docetaxel and ramucirumab versus docetaxel and ramucirumab alone in treating patients with non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Cemiplimab is a monoclonal antibody that stimulates the immune system by blocking the PD-1 pathway. Tumors use the PD-1 pathway to escape attacks from the immune system. By blocking the PD-1 pathway, cemiplimab may help the immune system recognize and attack tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Adding cemiplimab to usual treatment, docetaxel and ramucirumab, may kill more tumor cells compared to docetaxel and ramucirumab alone in treating patients with stage IV or recurrent non-small cell lung cancer.

Recruiting

1 award

Phase 2 & 3

19 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Durham VA Medical Center, Durham, NC?

Where is Durham VA Medical Center, Durham, NC located?

Who should I call to ask about financial aid or insurance network?

What insurance does Durham VA Medical Center, Durham, NC accept?

What awards or recognition has Durham VA Medical Center, Durham, NC received?